- Home
- A-Z Publications
- Current Topics in Medicinal Chemistry
- Previous Issues
- Volume 18, Issue 28, 2018
Current Topics in Medicinal Chemistry - Volume 18, Issue 28, 2018
Volume 18, Issue 28, 2018
-
-
The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy
Authors: Na Liu, Rongtong Zhao, Yue Ma, Dongyuan Wang, Chen Yan, Dongxian Zhou, Feng Yin and Zigang LiEpigenetics process is the heritable change in gene function that does not involve changes in the DNA sequence. Until now, several types of epigenetic mechanisms have been characterized, including DNA methylation, histone modification (acetylation, methylation, etc.), nucleosome remodeling, and noncoding RNAs. With the biological investigations of these modifiers, some of them are identified as promoters in the Read More
-
-
-
Epigenetic Targets and their Inhibitors in Cancer Therapy
Authors: Le Zhao, Yong-Tao Duan, Ping Lu, Zhi-Juan Zhang, Xiao-Ke Zheng, Jun-Lei Wang and Wei-Sheng FengEpigenetics is defined as the stable and heritable alternations in gene expression without changing the DNA nucleotide sequence. The initiation and progression of cancer result from not only genetic mutation, but also aberrant epigenetic regulation, such as DNA methylation and histones acetylation. Although Genetic alternations cannot be reversed, epigenetic modification is a dynamic and reversible process. Over the pa Read More
-
-
-
Histone Deacetylase Inhibitors in Cancer Therapy
Authors: Yijie Sun, Yanyi Sun, Saichao Yue, Yaohe Wang and Fanghui LuHistone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments has been discovered in a broad range of tumors contributing to the tumorigenesis through a serial of biological pathways. HDACs, therefore, are characterized as promising cancer therapeutic targets, and their inhibitors are under rapid d Read More
-
-
-
Structure, Functions and Selective Inhibitors of HDAC6
More LessHistone deacetylases 6 (HDAC6) has emerged as a promising target for the treatment of various human diseases including cancer, neurodegenerative disease and immunology due to its unique structure, substrate and biological functions. HDAC6 is involved in cell motility, cell survival, cell cycle progression, developmental events, prognosis as well as protein degradation and the involvement of HDAC6 in multipl Read More
-
-
-
DNA Methyltransferase Inhibitors and their Therapeutic Potential
Authors: Zehao Zhou, Huan-Qiu Li and Feng LiuAberrant DNA methylation at the 5-position of cytosine, catalyzed by DNA methyltransferases (DNMTs), is associated with not only various cancers by silencing of tumor suppressor genes but also other diseases. The DNMTs, especially the DNMT1, DNMT3A and DNMT3B, are often overexpressed in various cancer tissues and cell lines. DNMTs are important epigenetic targets for drug development since the DNA methylation is reve Read More
-
Volumes & issues
-
Volume 25 (2025)
-
Volume 24 (2024)
-
Volume 23 (2023)
-
Volume 22 (2022)
-
Volume 21 (2021)
-
Volume 20 (2020)
-
Volume 19 (2019)
-
Volume 18 (2018)
-
Volume 17 (2017)
-
Volume 16 (2016)
-
Volume 15 (2015)
-
Volume 14 (2014)
-
Volume 13 (2013)
-
Volume 12 (2012)
-
Volume 11 (2011)
-
Volume 10 (2010)
-
Volume 9 (2009)
-
Volume 8 (2008)
-
Volume 7 (2007)
-
Volume 6 (2006)
-
Volume 5 (2005)
-
Volume 4 (2004)
-
Volume 3 (2003)
-
Volume 2 (2002)
-
Volume 1 (2001)
Most Read This Month
Article
content/journals/ctmc
Journal
10
5
false
en
